Cell Therapeutics Reaches Pricing Agreement in Germany Drug Discovery & Development CTI is currently accruing patients into a Phase 3 trial comparing Pixuvri and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell NHL. Pixuvri does not have marketing approval in the United States. Date: December 4, 2013 ... |
